The role of PTEN as a cancer biomarker by McCabe, Nuala et al.
The role of PTEN as a cancer biomarker
McCabe, N., Kennedy, R. D., & Prise, K. M. (2016). The role of PTEN as a cancer biomarker. Oncoscience,




Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright 2016 The Authors
This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/),
which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:15. Feb. 2017
54www.impactjournals.com/oncoscience Oncoscience
www.impactjournals.com/oncoscience/ Oncoscience 2016, Vol.3, No.2
The role of PTEN as a cancer biomarker
Nuala McCabe, Richard D. Kennedy, Kevin M. Prise
THE PTEN TUMOUR SUPPRESSOR GENE
The phosphatase and tensin homologue, PTEN, 
was identified in 1997 and later found to be frequently 
disrupted in multiple sporadic tumour types and 
targeted by germline mutations in patients with cancer 
predisposition syndromes such as Cowden disease [1]. The 
principal catalytic function of PTEN is to dephosphorylate 
phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)
P3), which is a potent activator of 3-phosphoinositide-
dependent kinase (PDK) and AKT. As a consequence, 
loss of PTEN function leads to increased levels of 
PtdIns(3,4,5)P3 and activation of the phosphoinositide 
3-kinase (PI3K)–AKT pathway which stimulates cell 
growth and survival. Additionally, recent data demonstrate 
that nuclear PTEN has now been demonstrated to maintain 
genomic stability through regulation of RAD51, a key 
protein involved in double-strand break (DSB) repair and 
stabilisation of replication fork during replication stress 
[2]. These distinct functions of PTEN and associated 
cancer predisposing mutations, has caused great interest 
in PTEN as a cancer biomarker.
PTEN AS A BIOMARKER IN ESTIMATING 
RISK
Germline mutations of PTEN are the underlying 
genetic causes of related disorders clinically referred to as 
PTEN hamartoma syndromes (PHTS) including Cowden 
syndrome. Mutations responsible for these syndromes 
result in a non-functional or absent protein, which causes 
uncontrolled cell growth, leading to tumour (either benign 
or malignant) growth. Additionally these patients have a 
predisposition for cancer with increased lifetime risks for 
breast (85%), thyroid (35%), renal (33%), and endometrial 
(28%) cancers, colorectal cancers (9%) and melanoma 
(6%) [3].
PTEN AS A PROGNOSTIC BIOMARKER 
The cloning of the PTEN gene to human 
chromosome 10q23.3, was accompanied by detection of 
various types of mutations including homozygous deletion, 
frameshift, inframe deletion, truncation and point mutation 
[1]. Additionally post-translational modifications including 
phosphorylation, acetylation, methylation, oxidation have 
also been implicated in the loss of PTEN function and 
in the initiation of tumourigenesis [4].  Whether through 
mutation or epigenetic regulation, the loss or aberration 
of the PTEN gene/protein can have prognostic impact 
in the cancers which manifest these alterations. PTEN 
loss has been shown to be associated with poor outcome 
in a variety of cancers including prostate cancer (PCa), 
glioblastoma and colorectal cancer [1, 4]. For example 
approximately 2–14% of prostate cancer specimens were 
shown to harbour PTEN mutations, and 12–41% have 
copy number loss [4]. It has been demonstrated that there 
was a higher frequency of PTEN loss in more advanced 
castrate resistant PCa (CRPC) cases and that PTEN loss 
was associated with shorter progression-free survival time 
[4].
PTEN AS A PREDICTIVE BIOMARKER 
PTEN has been associated with response to 
conventional standard of care chemotherapy. PTEN-
negative tumours have also been shown to have shorter 
survival in the post-docetaxel abiraterone treatment setting 
compared with cases with preserved PTEN expression [5]. 
Additionally PTEN loss has previously been reported to be 
prognostic for outcome following radiotherapy in prostate 
cancer [4].  PTEN expression also shows promise as a 
predictive marker for targeted therapeutic agents including 
anti-EGFR mAbs [6], trastuzumab-based chemotherapy 
in breast cancer [7]. Additionally PTEN loss has been 
demonstrated to induce sensitivity to PARP1/2 inhibition 
in cell line models, however recent findings from TOPARP 
trial (NCT01682772) indicate that PTEN loss does not 
confer sensitivity to PARP inhibition using olaparib 
[8] suggesting that a greater understanding of the role 
of PTEN in DNA repair and therefore PARP inhibitor 
sensitivity will need to be gained. Additionally our lab 
has demonstrated a function for PTEN in controlling 
oxidative DNA damage was recently demonstrated and 
therapeutically exploited using an ataxia telangiectasia 
mutated (ATM) inhibitor [9]. We have demonstrated that 
the sensitivity of PTEN null cells to ATM inhibition was 
dependent of the generation of oxidative DNA damage, 
and independent of RAD51 function, suggesting further 
nuclear roles for PTEN. 
The utility of using PTEN as a biomarker of 
prognosis or predictor for drug response clearly needs 
further investigation. Only through a greater understanding 
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of the function played by PTEN in regulating various 
biological functions will its role as a biomarker be fully 
realised. Additionally it will be imperative to evaluate 
the monopoly of cancer associated mutations and post-
translational modifications which target these functions 
in clinical samples. This will be important in defining 
the best methods for detecting PTEN aberration for best 
clinical impact. 
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